| アブストラクト | BACKGROUND: Deterioration of diabetes control can be the first harbinger of pancreatic cancer. However, little is known about how to distinguish patients with pancreatic cancer-related diabetes deterioration from those with type 2 diabetes progression. We aimed to characterize the glycated hemoglobin (HbA(1c)) and body weight profile of pancreatic cancer patients with deteriorating diabetes before the cancer diagnosis. METHODS: Using data from the UK-based Clinical Practice Research Datalink (CPRD) GOLD, we established a study population including pancreatic cancer patients with diabetes deterioration in the >0.5-3 years before the cancer diagnosis and non-cancer patients with deterioration of type 2 diabetes (comparison group). Patients were considered to have diabetes deterioration if their glucose-lowering treatment was intensified. We characterized the longitudinal trajectories of HbA(1c) and body weight in pancreatic cancer patients compared with non-cancer patients before and after treatment intensification. RESULTS: The mean absolute increase in HbA(1c) from the pre-deterioration period, i.e. the time >1-2 years before treatment intensification, to the time of treatment intensification, was 1.5% +/- 1.6% in pancreatic cancer patients vs. 0.9% +/- 1.4% in non-cancer patients. After treatment intensification, mean HbA(1c) remained elevated in pancreatic cancer patients, while it returned to the pre-deterioration level in non-cancer patients. Body weight decreased by 1.9% +/- 6.4% in cancer patients and increased by 0.3% +/- 5.2% in non-cancer patients between the pre-deterioration period and treatment intensification, on average. CONCLUSIONS: Pancreatic cancer-related diabetes deterioration may frequently be characterized by pronounced increases in HbA(1c), persistent elevation of HbA(1c) after treatment intensification, and concomitant weight loss. |
|---|
| ジャーナル名 | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] |
|---|
| Pubmed追加日 | 2022/3/23 |
|---|
| 投稿者 | Mueller, Alexandra M; Meier, Christoph R; Jick, Susan S; Schneider, Cornelia |
|---|
| 組織名 | Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,;Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland;;Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.;Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; Boston;Collaborative Drug Surveillance Program, Lexington, MA, USA. Electronic address:;christoph.meier@usb.ch.;Boston Collaborative Drug Surveillance Program, Lexington, MA, USA; Boston;University School of Public Health, Boston, MA, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35314354/ |
|---|
